



an Open Access Journal by MDPI

The Role of Alarmins in Human Pathologies: Impact on Diagnostic and Therapeutic Approaches

Guest Editors:

Prof. Dr. Giuseppe Murdaca

Head of Allergology and Clinical Immunology Unit, Department of Internal Medicine, University of Genoa and San Bartolomeo Hospital, Sarzana, Italy

Prof. Dr. Sebastiano Gangemi

Department of Clinical and Experimental Medicine, School and Operative Unit of Allergy and Clinical Immunology, University of Messina, 98125 Messina, Italy

Deadline for manuscript submissions: closed (30 April 2024)

Message from the Guest Editors

Alarmins are endogenous proteins or peptides that are substitutively expressed and have chemotactic roles. When alarmins are released in excess as a result of injury or powerful stimuli, they cause the dangerous effects of a cytokine storm, resulting in the development of what have been recognized as "damage associated molecular models (DAMP)". These mediators have been shown to play a fundamental role in the pathogenesis of numerous allergic and immune-mediated diseases by the "IL-31/IL-33 axis", as well as in the neuroinflammatory processes involved in multiple brain conditions, including stroke and neurodegenerative diseases. Furthermore, alarmins also appear to be involved in metastatic progression and drug resistance of some forms of cancer, such as multiple myeloma. In the future, the assay of these cytokines could be useful for the diagnosis, staging and identification of specific therapeutic molecules capable of controlling their release and, thus, provide information on disease progression.



mdpi.com/si/106735







an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

 Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research. biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine* (*miscellaneous*))

Contact Us

Biomedicines Editorial Office MDPI, St. Alban-Anlage 66 4052 Basel, Switzerland Tel: +41 61 683 77 34 www.mdpi.com mdpi.com/journal/biomedicines biomedicines@mdpi.com X@Biomed_MDPI